|1.||Suzuki, Kengo: 3 articles (11/2013 - 07/2009)|
|2.||Yoshida, Eriko: 3 articles (11/2013 - 07/2009)|
|3.||Sugiyama, Akihiko: 2 articles (06/2010 - 07/2009)|
|4.||Mitra, Sharbanee: 2 articles (06/2010 - 07/2009)|
|5.||Yabuta, Yukinori: 2 articles (06/2010 - 07/2009)|
|6.||Arashida, Ryo: 2 articles (06/2010 - 07/2009)|
|7.||Nakano, Ryohei: 2 articles (06/2010 - 07/2009)|
|8.||Takeuchi, Takashi: 2 articles (06/2010 - 07/2009)|
|9.||Watanabe, Toshiaki: 1 article (11/2013)|
|10.||Yuasa, Masahiro: 1 article (11/2013)|
|1.||Colonic Neoplasms (Colon Cancer)
11/01/2013 - "From these findings, although the mechanism of the ACF-inhibiting effects of paramylon remains unclear, it is considered that β-glucans, such as paramylon and its isomer amorphous paramylon, have preventive effects against colon cancer and are more effective against the condition than Euglena. "
|2.||Atopic Dermatitis (Atopic Eczema)
06/01/2010 - "This study was designed to evaluate the suppressive effects of the oral administration of paramylon on the development of atopic dermatitis (AD)-like skin lesions induced by repeated application of 2,4,6-trinitrochlorobenzene (TNCB) in sensitized NC/Nga mice. "
06/01/2010 - "Oral administration of paramylon, a beta-1,3-D-glucan isolated from Euglena gracilis Z inhibits development of atopic dermatitis-like skin lesions in NC/Nga mice."
|3.||Body Weight (Weight, Body)
07/01/2009 - "Wistar stain male rats were orally administered paramylon (500, 1,000 and 2,000 mg/kg body weight) before treatment with a single intraperitoneal dose of 50% CCl(4) (2 ml/kg body weight). "
06/01/1976 - "Paramylon, in a dose of 1 mug/g body weight, injected intraperitoneally 24 hr after tumor implantation had an inhibitory effect on the tumor growth, although without causing complete regression of the tumor. "
|4.||Aberrant Crypt Foci
|5.||HIV Infections (HIV Infection)
|6.||Immunoglobulin E (IgE)